drugset / Trial / NCT03666871
CCR5-modified CD4+ T Cells for HIV Infection
Phase 1/2
Completed
30 enrolled
University of Cincinnati
Case Western Reserve University · collabUniversity of California, San Francisco · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects
Timeline
- Start
- 2019-06-12
- Primary completion
- 2024-01-31
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Expanded unmodified autologous CD4+ T cells | Cell therapy | 5e+09 cells | Intravenous |
| Comparator | Expanded unmodified autologous CD4+ T cells | Cell therapy | 4e+10 cells | Intravenous |
| Subject | SB-728-T | Cell therapy | 5e+09 cells | Intravenous |
| Subject | SB-728-T | Cell therapy | 4e+10 cells | Intravenous |